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OBJECTIVE: To evaluate the impact of a clinical pharmacy program on health outcomes in patients with type 2
diabetes undergoing insulin therapy at a teaching hospital in Brazil.
METHOD: A randomized controlled trial with a 6-month follow-up period was performed in 70 adults, aged 45
years or older, with type 2 diabetes who were taking insulin and who had an HbA1c level $8%. Patients in the
control group (CG) (n= 36) received standard care, patients in the intervention group (IG) (n = 34) received an
individualized pharmacotherapeutic care plan and diabetes education. The primary outcome measure was
change in HbA1c. Secondary outcomes included diabetes and medication knowledge, adherence to
medication, insulin injection and home blood glucose monitoring techniques and diabetes-related quality of
life. Outcomes were evaluated at baseline and 6 months using questionnaires.
RESULTS: Diabetes knowledge, medication knowledge, adherence to medication and correct insulin injection
and home blood glucose monitoring techniques significantly improved in the intervention group but remained
unchanged in the control group. At the end of the study, mean HbA1c values in the control group remained
unchanged but were significantly reduced in the intervention group. Diabetes-related quality of life
significantly improved in the intervention group but worsened significantly in the control group.
CONCLUSION: The program improved health outcomes and resulted in better glycemic control in patients with
type 2 diabetes undergoing insulin therapy.
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Outpatient Care.
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& INTRODUCTION
Diabetes mellitus (DM) is one of the most common non-
communicable diseases globally. In 2011, it was estimated
that 366 million people worldwide had DM, corresponding
to a global prevalence of 8.3%. Type 2 DM (T2DM) accounts
for the majority of these cases and 80% of people with DM
live in low- and middle-income countries (1). A recent study
estimated the prevalence of DM in Brazil at 5.6% (2).
The management of T2DM is complex, requiring long-
term continuous medical care and significant effort by the
patient regarding self-management activities (3). To enable
effective management of DM, multidisciplinary team
approaches are necessary and must rely on a well-
established relationship between an informed and involved
patient and a proactive team (3,4).
It is essential in this collaborative and integrated team
approach that individuals with diabetes assume an active
role in their care. Various strategies and techniques should
be used by professionals to provide adequate education on
and to support the development of problem-solving skills in
various aspects of diabetes management. Any plan should
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recognize diabetes self-management education and ongoing
diabetes support as integral components of care. Diabetes
self-management education is the continuous process of
facilitating the knowledge, skills and abilities necessary for
diabetes self-care. The objectives of this educational
approach are to support informed decision-making, self-
care behaviors, problem-solving and active collaboration
with the health care team to improve clinical outcomes,
health status and quality of life (3,4).
The expansion of the diabetes educator role to other
professionals, such as pharmacists, has been recognized
(3-6). Moreover, pharmacists are uniquely positioned to
educate patients on the appropriate utilization of medica-
tion through the elaboration, implementation and monitor-
ing of pharmacotherapeutic plans intended to produce
specific outcome improvements (3,5,7).
& MATERIALS AND METHODS
Study design
The study was a randomized controlled trial (RCT) with a
6-month follow-up period. It was performed in the diabetes
outpatient clinic of Hospital das Clı´nicas da Faculdade de
Medicina da Universidade de Sa˜o Paulo, which is a tertiary
facility hospital located in the city of Sa˜o Paulo, Brazil.
Patients were included in the study if they were aged 45
years or older, diagnosed with T2DM and on prescription
insulin and if they had an HbA1c level exceeding 8%.
Patients were not included if they were unable to develop
self-management activities and/or they had participated in
DM educational programs in the last 3 months.
Eligible patients were invited to participate and for those
who accepted, additional information was provided before
they were asked to sign the study’s consent form. After
recruitment, patients were randomly assigned to one of two
groups: the control group (CG) or the intervention group (IG).
The group allocationswere assigned by simple randomization.
After randomization, all patients were individually
interviewed to obtain socio-demographic information, a
clinical history of diabetes and information on current
medication use. Assessments of diabetes and medication
knowledge, adherence to medication, insulin injection and
home blood glucose monitoring techniques, HbA1c values
and diabetes-related quality of life were also performed.
Patients in the IG had monthly individual appointments
and those in the CG were observed at the initial and final
assessments (Figure 1).
Patients randomized to the CG received standard care
during the study period. Although they did not receive
advice from the clinical pharmacist, they were allowed to
request information anytime during the study.
Interventions
For each patient randomized to the IG, an individualized
pharmacotherapeutic care plan (PCP) was designed based
on necessities identified in the first interview. Advice
focused on indication, proper dosage, side effects and
adequate storage of medication. Pill organizers were given
to each patient along with verbal directions on their
assembly. Written guidance on prescriptions was provided
at each consult. Additionally, a diabetes education protocol
was developed to provide basic information on acute and
chronic complications, the importance of lifestyle changes
(healthy diet, physical activity, smoking cessation), regular
foot inspections, the importance of home blood glucose
monitoring and other topics. Clinical pharmacist recom-
mendations, such as insulin dose adjustments, were
discussed with the physician when necessary.
Outcomes
The primary outcome measure was change in HbA1c
level. HbA1c levels were measured using the high-perfor-
mance liquid chromatography (HPLC) method.
Diabetes and medication knowledge was assessed using
questionnaires developed based on previous publications
(8,9). Self-reported adherence to medication was evaluated
using the Morisky-Green questionnaire (10,11) and the
Adherence to Medicines Questionnaire (AMQ), which has
been validated in the Brazilian population (12). Insulin
injection and home blood glucose monitoring techniques
were assessed by instruments standardized in our practice
(13) and diabetes-related quality of life was determined
using the validated Brazilian version of Diabetes Quality of
Life Measure (14).
Statistical analysis
Comparisons were made between the data at the initial
and final assessments using appropriate statistical tests as
follows: the chi-square test was used for categorical data
and the paired t-test was utilized for normally distributed
continuous data. Comparisons between HbA1c levels and
other outcomes were performed using analysis of variance
(ANOVA) and Bonferroni’s correction.
Figure 1 - Flow chart showing the various phases of the study.
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All analyses were performed using the Statistical Analysis
System (SAS) version 8.0 and the Statistical Package for the
Social Sciences (SPSS) version 15.0.
Ethics
The study protocol was approved by the Research Ethics
Committee of the Hospital das Clı´nicas da Faculdade de
Medicina da Universidade de Sa˜o Paulo.
& RESULTS
Seventy-eight patients were initially enrolled in the study,
namely, 41 in the CG and 37 in the IG. During the study
period, 8 patients were excluded (5 in the CG and 3 in the
IG) because they missed appointments. Thirty-six patients
in the CG and 34 in the IG completed the study (Figure 1).
The demographic characteristics of the patients are shown
in Table 1; the two groups were homogeneous with respect
to all variables.
In the IG, the diabetes knowledge score increased from
9.91¡2.69 to 15.74¡3.03 and medication knowledge
increased from 4.47¡0.84 to 6.58¡1.29. No changes were
observed in the CG for either knowledge outcome (Table 2).
According to both questionnaires used to estimate
adherence to medication, adherence in the IG improved
significantly, namely, from 17.6% to 70.6% adherent patients
according to the Morisky-Green questionnaire and from
41.7% to 52.9% adherent patients based on the AMQ
responses. The percentage of adherent patients in the CG
remained unchanged (Table 2).
The scores for insulin injection and blood glucose
monitoring techniques significantly increased at the end of
the study in the IG (66.61¡15.41 to 87.81¡10.89 and
6.85¡0.93 to 8.88¡1.04, respectively) but remained
unchanged in the CG (Table 2).
The baseline mean serum HbA1c level was 9.61¡1.38 in
the CG and 9.78¡1.55 in the IG. At the end of the study, the
mean HbA1c level changed to 9.53¡1.68 in the CG but
decreased significantly to 9.21¡1.41 in the IG, correspond-
ing to a decrease of 0.57%.
Diabetes-related quality of life improved significantly in
the IG by the end of the study, whereas there was a
significant decrease in quality of life in the CG (Table 2).
No patients in the CG requested information during the
study.
& DISCUSSION
The practice of pharmaceutical care in Brazil has grown in
recent years and in patients with diabetes, this care occurs
mainly in primary and secondary health care settings (15-
18).
This study was designed to evaluate the impact of
pharmaceutical care in patients with T2DM treated at a
tertiary health care facility, where patients are seen by a
multidisciplinary team of physicians, nurses, psychologists,
dieticians and podiatrists. Therefore, this study was unique
because the clinical pharmacist worked directly with other
professionals involved in patient care and participated in
discussions regarding the best approach to patient treat-
ment.
Few studies on pharmaceutical care have evaluated
patients’ diabetes knowledge. Similar to our study, sig-
nificant increases in diabetes knowledge in the IG were
reported by Fornos et al. (19) and by Mehuys et al. (20).
At the beginning of our study, patient knowledge of
medications was low in both groups, mainly due to a lack of
knowledge regarding the main adverse reactions and how
to respond to missing a dose. The instructions regarding
these aspects, as well as the medication names, indications
and doses, most likely contributed to the significant increase
in the scores at the end of the study in the IG. Other studies
have reported similar results (19,21,22) and similar to our
findings, Wermeille et al. attributed the minimal knowledge
at baseline to not knowing the names of the medicines or
how to respond to a missed dose (22).
Nonadherence to medications has been reported as the
primary factor responsible for unscheduled consults and
hospitalizations among patients with diabetes (23). Therefore,
correct medication use is essential for treatment success
among patients with this disease. Adherence is a complex
component of treatment that is influenced by several factors
directly related to patient behavior. Thus, both the ques-
tionnaires utilized to estimate self-reported adherence aim to
identify and evaluate some of these aspects.
At the end of our study, 70.6% of the patients in the IGwere
adherent according to the Morisky-Green questionnaire and
52.9% were adherent according to the AMQ questionnaire.
The percentage of adherent patients according to theMorisky-
Green questionnaire in the IG at the end of the study is similar
to the 72% reported by Jarab et al. (2012) using the same
questionnaire (24). These values correspond to literature
reports of compliance ranging from 36% to 85% for patients
with diabetes (25), as well as to other studies evaluating
adherence in pharmaceutical care programs (16,21).
Our study did not show significant inverse correlations
between the number of prescribed medications and adher-
ence, in contrast to observations in other studies (25,26).
T2DM is a progressive disease and several years after
diagnosis, most patients develop secondary insulin defi-
ciency and require daily insulin injections. Therefore, insulin
injection and blood glucose self-monitoring techniques are
important components of diabetes self-management in
patients taking insulin (4).
At baseline, the most common errors regarding insulin
use were related to the use of the insulin bottle for longer
than recommended after opening (30 days), not washing
hands before the injection, not homogenizing the NPH
insulin before dispensing the dose and not waiting 5
seconds before removing the syringe after the injection. At
the end of the study, the major improvements observed in
the IG were related to proper homogenization of NPH
Table 1 - Baseline demographics of the study participants.
Variable Control Group (n=36) Intervention Group (n =34) p Total
Age (years) (mean (SD)) 61.58 (8.14) 61.91 (9.58) 0.877 61.74 (8.81)
Male (n/total (%)) 14/36 (38.9) 13/34 (38.2) 0.955 27/70 (38.6)
Duration of diabetes (years), (mean (SD)) 14.92 (8.49) 14.56 (7.40) 0.852 14.74 (7.92)
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insulin and appropriate reading of the graduation of the
syringes. Regarding home blood glucose monitoring, the
major technical improvement observed in the IG was related
to the appropriate puncture site on the finger. Nevertheless,
we did not identify previously published studies that
evaluated these aspects in pharmaceutical care programs.
The significant reduction in mean HbA1c (0.57%
decrease) in the IG was comparable to that reported in
other randomized controlled trials with the same follow-up
period; specifically, the decrease was similar to the 0.6%
decrease reported by Moura˜o et al. (18) and Mehuys et al.
(20) and slightly lower than the 0.8% decrease reported by
Jarab et al. (24). Despite the similarities between the studies,
it is worth noting that the study published by Moura˜o et al.
(18) was conducted in a primary health care setting and
included patients with HbA1c.7% who were only on oral
antidiabetic medication. The study reported byMehuys et al.
(20) was performed in community pharmacies and only
approximately 10% of the participants were on prescription
insulin. The study performed by Jarab et al. (24) included
patients with HbA1c levels above 7.5% who had a shorter
duration of disease compared with our population, which
may explain why approximately 70% of the patients were
on insulin therapy. Additionally, the reduction in mean
HbA1c observed in our study was similar to the 0.62%
reduction in the IG described in a meta-analysis performed
by Machado et al. (27), but it was lower than the 0.76%
reduction found in the meta-analysis by Collins et al. (28).
A non-randomized study performed in the city of
Ribeira˜o Preto, Sa˜o Paulo, Brazil, with patients of similar
age to those in our study revealed a significant reduction in
mean HbA1c (0.9%) in the IG after 12 months of follow-up
(16). Similarly to the study cited, other studies have reported
greater reductions in HbA1c (1.3% and 3.4%), probably due
to a longer follow-up period (usually 12 months) (19,29-31).
The differences between the reductions in HbA1c values
reported in the aforementioned studies could also be due to
the characteristics of the study population. The patients in
this study had difficulty managing T2DM; a prolonged time
had elapsed since disease diagnosis; and all the patients
were on prescription insulin, most as intensive therapy.
Furthermore, social and cultural aspects, such as low health
literacy, partially explain the poor glycemic control and
eventually presented as deficiencies in knowledge of
diabetes, medications and necessary techniques for self-
management at the beginning of the study.
Studies have shown that certain classes of antidiabetic
medication, including the most recent glucagon-like peptide 1
(GLP-1) agonists and dipeptidyl peptidase 4 (DPP-4) inhibi-
tors, reduce HbA1c by a mean of 0.5% to 1%. Thus, the 0.57%
decrease reported in our study is clinically relevant (32).
The significant improvement in diabetes-related quality
of life in the IG as well as the decreased diabetes-related
quality of life in the CG were unexpected. As quality of life
encompasses several dimensions, changes typically only
become apparent in the medium or long term and are,
therefore, difficult to detect in a six-month period or in a
small cohort, such as was the case in our study. Indeed, Al
Mazroui et al. reported a significant increase in quality of
life in the IG after 12 months of intervention according to a
general health-related quality of life questionnaire (SF36
Questionnaire) (21).
We can likely attribute the reduction in HbA1c in the IG
patients to the positive results in the evaluated secondary
outcomes (16,21,33).
The improvement in the outcomes measured in our study
are a result of individualized instructions related to pharma-
cotherapy provided by a clinical pharmacist and the
educational approach to diabetes self-management activities,
as we consider pharmacists to be diabetes educators (34,35).
Table 2 - Outcome changes from baseline in the control and intervention groups.
Variable Assessment
Control Group
(n=36)
Intervention Group
(n =34) p*
Diabetes knowledge (score, mean ¡ SD) Initial 9.72¡2.71 9.91¡2.69 .0.999
Final 9.75¡2.69 15.74¡3.03 ,0.001
p# .0.999 ,0.001
Medication knowledge (score, mean ¡ SD) Initial 3.94¡0.99 4.47¡0.84 0.118
Final 3.85¡0.99 6.58¡1.29 ,0.001
p# .0.999 ,0.001
Adherence, Morisky-Green (% adherent patients) Initial 27.8% 17.6% 0.313
Final 25% 70.6% ,0.001
p# .0.999 ,0.001
Adherence, AMQ (% adherent patients) Initial 30.6% 47.1% 0.917
Final 25% 52.9% 0.016
p# 0.500 0.039
Insulin injection technique (% correct) Initial 59.09¡18.24 66.61¡15.41 0.404
Final 57.68¡18.21 87.81¡10.89 ,0.001
p# .0.999 ,0.001
Home blood glucose monitoring technique (score, mean ¡ SD) Initial 6.31¡1.41 6.85¡0.93 0.364
Final 6.25¡1.18 8.88¡1.04 ,0.001
p# .0.999 ,0.001
HbA1c (%, mean ¡ SD) Initial 9.61¡1.38 9.78¡1.55 .0.999
Final 9.53¡1.68 9.21¡1.41 .0.999
p# .0.999 ,0.001
Diabetes-related quality of life (score, mean ¡ SD) Initial 162.53¡9.71 157.21¡13.28 0.354
Final 166.36¡9.94 152.06¡14.98 ,0.001
p# ,0.001 ,0.001
p* for comparisons between groups.
p# for analyses between the initial and final assessments within a group.
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This combination is intended to improve patient quality of
life, which is consistent with the philosophy of pharmaceu-
tical care (7).
This study had certain limitations, such as the small sample
size, the short follow-up period and the inherent inability to
control for all confounding factors in the outcome analysis.
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